Hormonal Control: ADH and Aldosterone - Anatomy and Physiology

SECTION 1

Historical Context & Motivation

The study of how the body regulates its internal fluid environment is one of the great narratives in physiology, stretching from nineteenth-century observations of kidney function to modern molecular endocrinology. Clinicians long recognized that certain patients produced enormous volumes of dilute urine—a condition eventually named diabetes insipidus—yet they lacked the mechanistic framework to explain why. The quest to understand this phenomenon drove researchers toward the discovery of two hormones that act on the kidney to fine-tune water reabsorption and sodium retention: antidiuretic hormone (ADH) and aldosterone. Together, these hormones integrate neural, cardiovascular, and renal signals to preserve homeostasis under conditions ranging from dehydration to hemorrhage.

1913 • Posterior Pituitary Extracts

Oliver and Schäfer's earlier work on pituitary extracts was extended by researchers who demonstrated that posterior pituitary fractions reduce urine output in animals, providing the first experimental evidence for an antidiuretic substance of hormonal origin.

1947 • Identification of ADH (Vasopressin)

Vincent du Vigneaud and colleagues determined the amino acid sequence of vasopressin (ADH), a nonapeptide synthesized in the hypothalamus. Du Vigneaud later synthesized the peptide in vitro, earning the 1955 Nobel Prize in Chemistry.

1953 • Aldosterone Isolated

Simpson and Tait isolated aldosterone from the adrenal cortex, characterizing it as the principal mineralocorticoid controlling sodium reabsorption and potassium secretion in the distal nephron.

1960s • Renin–Angiotensin–Aldosterone System

Research groups elucidated the full renin–angiotensin–aldosterone system (RAAS), revealing how juxtaglomerular cells sense blood pressure and trigger a cascade culminating in aldosterone release from the zona glomerulosa.

1990s • Aquaporin Discovery

Peter Agre identified aquaporin-2 (AQP2) water channels in the collecting duct, finally explaining the molecular mechanism by which ADH increases membrane water permeability—work that earned the 2003 Nobel Prize in Chemistry.

The central question that unites these discoveries is deceptively simple: How does the body decide how much water and salt to keep versus excrete? The answer involves two hormonal axes—one centered on water conservation (ADH), the other on sodium retention (aldosterone)—that operate through distinct receptors, signaling cascades, and nephron targets yet ultimately converge to maintain plasma osmolarity near 285–295 mOsm/L and mean arterial pressure within a narrow physiological range.

SECTION 2

Core Principles & Definitions

Before examining ADH and aldosterone in detail, it is essential to establish the foundational concepts governing renal water and electrolyte handling. The kidney processes approximately 180 liters of glomerular filtrate per day, yet only about 1–2 liters of urine are typically excreted. This extraordinary reabsorptive capacity is modulated by hormonal signals that alter the permeability and transport properties of specific nephron segments, particularly the distal convoluted tubule (DCT) and the collecting duct. Understanding these principles requires familiarity with osmolarity, the countercurrent multiplier system, and the distinction between obligatory and facultative water reabsorption.

Osmolarity & Tonicity

Osmolarity measures the total solute concentration per liter of solution (mOsm/L). Plasma osmolarity is tightly regulated at ~290 mOsm/L. ADH secretion is triggered by as little as a 1–2% increase above this set point, detected by hypothalamic osmoreceptors.

ADH (Vasopressin)

A nine-amino-acid peptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus, stored in the posterior pituitary, and released in response to elevated plasma osmolarity or decreased blood volume. It acts on V₂ receptors in the collecting duct to insert aquaporin-2 channels.

Aldosterone

A steroid hormone produced by the zona glomerulosa of the adrenal cortex. It is stimulated primarily by angiotensin II and elevated plasma K⁺. Aldosterone binds intracellular mineralocorticoid receptors in principal cells of the DCT and collecting duct, upregulating ENaC sodium channels and Na⁺/K⁺-ATPase activity.

RAAS Cascade

Decreased renal perfusion pressure stimulates renin release from juxtaglomerular cells. Renin cleaves angiotensinogen → angiotensin I, which is converted to angiotensin II by ACE in the lungs. Angiotensin II stimulates aldosterone secretion, vasoconstriction, and ADH release.

Negative Feedback Loops

Both hormones operate within classic negative feedback circuits. Restoration of normal osmolarity suppresses ADH release, while restoration of blood volume and sodium balance suppresses renin secretion, closing the RAAS loop. ANP (atrial natriuretic peptide) provides an additional counter-regulatory signal.

✦

KEY TAKEAWAY

Think of ADH and aldosterone as two complementary control knobs on a building's plumbing system. ADH adjusts the water permeability of the pipes—when ADH is high, the collecting duct lets water flow back into the body, concentrating the urine. Aldosterone adjusts the sodium pumps—when aldosterone is high, the system actively retrieves sodium (and water follows osmotically). One hormone controls the 'permeability gate'; the other controls the 'active pump.' Together, they determine both the volume and the concentration of the final urine output.

SECTION 3

Visual Explanation: ADH and Aldosterone Pathways

The diagram illustrates the two parallel hormonal pathways. On the left (cyan), increased plasma osmolarity activates hypothalamic osmoreceptors, leading to ADH release from the posterior pituitary, which inserts AQP2 channels in the collecting duct. On the right (violet), decreased blood pressure activates the RAAS cascade, culminating in aldosterone-mediated sodium reabsorption. Note the dashed crosslink: angiotensin II also stimulates ADH release, demonstrating pathway convergence.

Several features of this diagram deserve attention. First, the two pathways originate from different primary stimuli: osmolarity for ADH and blood pressure/volume for aldosterone, although both stimuli can activate either axis to varying degrees. Second, the effector mechanism differs fundamentally—ADH increases membrane permeability to water via channel insertion (a rapid, post-translational event), whereas aldosterone alters gene transcription to synthesize new transport proteins (a slower genomic response requiring 30–60 minutes). Third, note that angiotensin II acts as an integrative node: it stimulates aldosterone secretion, promotes ADH release, triggers systemic vasoconstriction, and enhances proximal tubular sodium reabsorption, making it arguably the most powerful effector molecule in the fluid balance system.

SECTION 4

Cellular and Molecular Mechanisms

ADH: The Aquaporin Insertion Pathway

ADH (also called arginine vasopressin, AVP) binds to V₂ receptors on the basolateral membrane of principal cells in the collecting duct. These receptors are Gₛ-protein coupled and activate adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) monomers stored in cytoplasmic vesicles. The phosphorylated AQP2 vesicles then translocate to the apical membrane and fuse via exocytosis, dramatically increasing the number of water channels available for osmotic water reabsorption. Water enters through AQP2 at the apical surface and exits via constitutively expressed AQP3 and AQP4 channels at the basolateral surface, returning to the peritubular capillaries. When ADH levels fall, AQP2 channels are endocytosed back into the cytoplasm, and the apical membrane returns to its baseline low-permeability state.

Aldosterone: The Genomic Pathway

Aldosterone, being a lipophilic steroid hormone derived from cholesterol, crosses the plasma membrane of principal cells in the late DCT and cortical collecting duct and binds to intracellular mineralocorticoid receptors (MR). The hormone-receptor complex dimerizes, translocates to the nucleus, and acts as a transcription factor binding to hormone response elements on target genes. The genomic effects of aldosterone include upregulation of epithelial sodium channels (ENaC) on the apical membrane, increased synthesis of basolateral Na⁺/K⁺-ATPase pumps, and enhanced expression of mitochondrial enzymes that generate ATP to fuel the pump. The net effect is increased Na⁺ reabsorption from the tubular lumen into the blood, with K⁺ (and H⁺) secreted into the lumen in exchange. Because sodium reabsorption creates an osmotic gradient, water follows passively, expanding extracellular fluid volume and raising blood pressure.

⚠

Clinical Connection

The enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) protects mineralocorticoid receptors from activation by cortisol, which circulates at concentrations ~100× higher than aldosterone. When this enzyme is inhibited—for example, by glycyrrhizic acid in licorice—cortisol occupies MRs, producing pseudohyperaldosteronism: sodium retention, hypokalemia, and hypertension.

Quantitative Relationships

OSMOLARITY EQUATION

Plasma Osmolarity ≈ 2[Na⁺] + [Glucose]/18 + [BUN]/2.8

Where [Na⁺] is in mEq/L, [Glucose] in mg/dL, and [BUN] in mg/dL. Sodium and its accompanying anions account for ~275 of the ~290 mOsm/L, underscoring why aldosterone-driven Na⁺ changes profoundly affect osmolarity.

FREE WATER CLEARANCE

C_H₂O = V − C_osm = V − (U_osm × V) / P_osm

C_H₂O = free water clearance (mL/min), V = urine flow rate, U_osm = urine osmolarity, P_osm = plasma osmolarity. When ADH is high, C_H₂O becomes negative (free water is retained); when ADH is absent, C_H₂O is positive (dilute urine is excreted).

TRANSTUBULAR K⁺ GRADIENT (TTKG)

TTKG = (U_K × P_osm) / (P_K × U_osm)

U_K and P_K are urine and plasma potassium concentrations, respectively. A TTKG > 7 suggests aldosterone-driven K⁺ secretion; values < 3 suggest hypoaldosteronism.

SECTION 5

Nephron Segment–Specific Actions

Understanding where along the nephron ADH and aldosterone exert their effects clarifies how the kidney can independently regulate water balance and sodium balance—a distinction of immense clinical significance. The proximal tubule reabsorbs roughly 65% of filtered sodium and water isosmotically and is largely independent of either hormone. The thick ascending limb of the loop of Henle reabsorbs NaCl without water (generating the corticomedullary osmotic gradient), and the thin descending limb allows water reabsorption but not salt. It is in the distal nephron—the DCT, connecting tubule, and collecting duct—where fine hormonal regulation occurs.

Schematic of the nephron highlighting hormonal targets. The DCT (violet border) is the primary site for aldosterone-mediated sodium reabsorption via ENaC. The collecting duct (cyan border) is the target for ADH-mediated water reabsorption via AQP2 channels. Both hormones also act on the cortical collecting duct. The medullary osmotic gradient (300–1200 mOsm/L) provides the driving force for ADH-dependent water reabsorption.

Feature	ADH (Vasopressin)	Aldosterone
Chemical class	Nonapeptide (9 amino acids)	Steroid (mineralocorticoid)
Source	Hypothalamus (SON, PVN) → posterior pituitary	Adrenal cortex (zona glomerulosa)
Primary stimulus	↑ Plasma osmolarity (>295 mOsm/L)	Angiotensin II, ↑ plasma K⁺
Receptor type	V₂ (Gₛ-coupled, basolateral)	Intracellular MR (nuclear receptor)
Mechanism	cAMP → PKA → AQP2 vesicle trafficking	Gene transcription → ENaC, Na⁺/K⁺-ATPase
Primary effect	↑ Water reabsorption (↓ osmolarity)	↑ Na⁺ reabsorption, ↑ K⁺ secretion
Onset of action	Minutes (vesicle trafficking)	30–60 minutes (genomic)
Nephron target	Collecting duct (principal cells)	Late DCT, cortical collecting duct

Side-by-side comparison of ADH and aldosterone

SECTION 6

Worked Example: Clinical Scenario Analysis

Consider a patient who presents after running a marathon on a hot day without adequate fluid replacement. Labs reveal plasma osmolarity of 310 mOsm/L, plasma Na⁺ of 152 mEq/L, low blood pressure, and concentrated, dark urine with osmolarity of 900 mOsm/L. Let us trace the hormonal response and verify it with the free water clearance calculation.

Dehydrated Marathon Runner: Predicting Hormonal and Renal Responses

1
Step 1 — Identify the Physiological Derangement

The patient exhibits hyperosmolarity (310 mOsm/L vs. normal 285–295) and hypovolemia (low BP from fluid loss through sweating). Both stimuli converge to activate compensatory hormonal responses.

Primary derangements: ↑ osmolarity (310 mOsm/L), ↓ blood volume/BP
2
Step 2 — Predict ADH Response

Hypothalamic osmoreceptors detect the elevated plasma osmolarity and trigger robust ADH release from the posterior pituitary. Additionally, decreased blood volume is detected by arterial baroreceptors and atrial volume receptors, which send afferent signals via CN IX and X to the hypothalamus, further stimulating ADH secretion. With high ADH, AQP2 channels are maximally inserted in the collecting duct, producing concentrated urine.

ADH is HIGH → maximal AQP2 insertion → U_osm = 900 mOsm/L (concentrated urine)
3
Step 3 — Predict Aldosterone Response

Low blood pressure decreases renal perfusion, stimulating renin release from juxtaglomerular cells. The RAAS cascade generates angiotensin II, which stimulates aldosterone secretion from the zona glomerulosa. Aldosterone acts on the DCT and collecting duct to increase Na⁺ reabsorption via ENaC, with water following osmotically, partially restoring blood volume.

Aldosterone is HIGH → ↑ Na⁺ reabsorption → ↑ blood volume → gradual BP restoration
4
Step 4 — Calculate Free Water Clearance

Assume urine flow rate V = 0.5 mL/min (oliguria due to water conservation). Using the formula C_H₂O = V − (U_osm × V) / P_osm: C_H₂O = 0.5 − (900 × 0.5) / 310 = 0.5 − 1.45 = −0.95 mL/min

C_H₂O = −0.95 mL/min (negative value confirms net free water retention)
5
Step 5 — Interpret the Integrated Response

The negative free water clearance confirms that the kidneys are retaining water relative to solute—exactly what is expected when ADH is elevated. Combined with aldosterone-driven sodium retention, the body simultaneously conserves water (lowering osmolarity back toward normal) and restores intravascular volume (raising BP). This dual-hormone response illustrates the elegance of integrated neuroendocrine feedback: the same clinical scenario activates both axes through different sensor mechanisms to achieve complementary endpoints.

Both ADH and aldosterone are maximally active, restoring both osmolarity and blood pressure toward normal

SECTION 7

Clinical Correlations: When the System Fails

Disruptions to ADH and aldosterone signaling produce predictable clinical syndromes that serve as powerful illustrations of normal physiology. Understanding these pathological states reinforces the roles of each hormone and highlights how tightly controlled fluid and electrolyte balance must be.

Disorder	Hormonal Defect	Key Findings
Central Diabetes Insipidus	Insufficient ADH production (hypothalamic/pituitary damage)	Polyuria (up to 20 L/day), polydipsia, very dilute urine (<200 mOsm/L), ↑ plasma osmolarity. Responds to exogenous desmopressin (dDAVP).
Nephrogenic Diabetes Insipidus	Kidney resistance to ADH (V₂ receptor or AQP2 defect)	Same presentation as central DI, but does NOT respond to desmopressin. Caused by lithium use, hypercalcemia, or genetic mutations.
SIADH	Excess ADH secretion (ectopic tumor, CNS disorders, drugs)	Hyponatremia (dilutional), concentrated urine (>100 mOsm/L), decreased plasma osmolarity, euvolemia (no edema). Treated with fluid restriction, V₂ receptor antagonists (vaptans).
Primary Hyperaldosteronism (Conn syndrome)	Excess aldosterone (adrenal adenoma or hyperplasia)	Hypertension, hypokalemia, metabolic alkalosis, suppressed renin. Treated with spironolactone or surgical resection.
Addison Disease	Insufficient aldosterone and cortisol (adrenal destruction)	Hypotension, hyperkalemia, hyponatremia, metabolic acidosis, salt craving. Life-threatening in adrenal crisis.

Clinical disorders of ADH and aldosterone

✦

KEY TAKEAWAY

Each clinical disorder can be thought of as a 'gain-of-function' or 'loss-of-function' experiment performed by disease on the body's control system. SIADH is like a thermostat stuck on 'heat'—the body keeps retaining water even though it doesn't need to, diluting plasma sodium. Diabetes insipidus is a thermostat that is disconnected entirely—the collecting duct cannot respond to the signal, and water pours out as dilute urine. Similarly, Conn syndrome represents an aldosterone system locked in the 'on' position, driving relentless sodium retention and potassium wasting. Recognizing the pattern of electrolyte and volume disturbances in each disorder is the key to rapid clinical diagnosis.

SECTION 8

Connections to Advanced Renal and Cardiovascular Physiology

ADH and aldosterone do not operate in isolation; they are embedded within a broader neurohumoral network that includes the sympathetic nervous system, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and the local renal prostaglandin and kallikrein-kinin systems. Advanced study of these interactions is essential for understanding conditions such as congestive heart failure, cirrhosis, and nephrotic syndrome, where multiple hormonal axes are activated simultaneously in maladaptive ways.

Concept in This Lesson	Advanced Extension
ADH acts on V₂ receptors in the collecting duct	ADH also acts on V₁ₐ receptors on vascular smooth muscle (vasoconstriction) and V₁ᵦ receptors on corticotrophs (ACTH release). V₂ receptor antagonists (tolvaptan, conivaptan) are used in heart failure and SIADH management.
Aldosterone promotes Na⁺ reabsorption via ENaC	Aldosterone has non-genomic (rapid) effects on the cardiovascular system, including endothelial dysfunction, myocardial fibrosis, and inflammation. MR antagonists (spironolactone, eplerenone) reduce mortality in heart failure independently of their renal effects.
RAAS produces angiotensin II	Tissue-level RAAS exists in the heart, brain, and adipose tissue. ACE inhibitors and ARBs interrupt the cascade at different points; their organ-protective effects extend beyond blood pressure reduction.
Negative feedback closes the loop	In heart failure, persistent RAAS activation despite volume overload exemplifies 'cardiorenal syndrome'—a pathological positive feedback cycle where declining cardiac output perpetuates renal sodium and water retention.
ANP opposes ADH/aldosterone	BNP (from ventricles) is a clinical biomarker for heart failure severity. Sacubitril (neprilysin inhibitor) prevents BNP degradation, enhancing natriuresis; combined with an ARB, it forms the class of angiotensin receptor-neprilysin inhibitors (ARNIs).

Bridges to advanced topics in renal and cardiovascular physiology

As you progress into pathophysiology, pharmacology, and clinical medicine, you will encounter ADH and aldosterone repeatedly in contexts ranging from fluid resuscitation protocols to the management of electrolyte emergencies. The mechanistic framework established in this lesson—stimulus detection, hormonal release, receptor signaling, effector response, and negative feedback—serves as a template for understanding virtually every endocrine axis in the body.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient drinks 2 liters of pure water rapidly. Describe the expected changes in plasma osmolarity, ADH levels, urine osmolarity, and urine volume over the next 2 hours. Why does aldosterone remain relatively unchanged in this scenario?

Show answer

Rapid water intake dilutes plasma solutes, decreasing plasma osmolarity below ~285 mOsm/L. Hypothalamic osmoreceptors detect this fall and suppress ADH release from the posterior pituitary. Without ADH, AQP2 channels are endocytosed from the collecting duct apical membrane, rendering it impermeable to water. Consequently, urine osmolarity drops to as low as 50–100 mOsm/L, and urine volume increases markedly (water diuresis). Aldosterone remains relatively unchanged because the primary stimulus for the RAAS—decreased blood pressure or elevated K⁺—is not significantly triggered by isotonic volume expansion. The excess water primarily dilutes osmolarity without substantially altering sodium delivery to the macula densa or systemic perfusion pressure.

Question 2: BASIC CALCULATION

A patient has the following lab values: plasma Na⁺ = 140 mEq/L, glucose = 90 mg/dL, BUN = 14 mg/dL. Calculate the estimated plasma osmolarity using the formula: Osmolarity ≈ 2[Na⁺] + [Glucose]/18 + [BUN]/2.8. Is this value within the normal range?

Show answer

Substituting the given values: Osmolarity ≈ 2(140) + 90/18 + 14/2.8 = 280 + 5 + 5 = 290 mOsm/L. The normal range for plasma osmolarity is approximately 285–295 mOsm/L, so 290 mOsm/L falls squarely within normal limits. At this osmolarity, ADH secretion is at a basal low level—sufficient to prevent excessive diuresis but not high enough to produce maximally concentrated urine. This is the physiological set point around which the osmoreceptor-ADH feedback loop oscillates.

Question 3: INTERMEDIATE

A patient on lithium therapy presents with a urine output of 8 L/day and urine osmolarity of 120 mOsm/L despite elevated plasma ADH levels. (a) What is the most likely diagnosis? (b) Would administering exogenous desmopressin correct the polyuria? (c) What is the underlying molecular defect?

Show answer

(a) The diagnosis is nephrogenic diabetes insipidus (NDI). Lithium accumulates in collecting duct principal cells via ENaC and interferes with AQP2 expression and V₂ receptor signaling. (b) Exogenous desmopressin (a V₂ receptor agonist) would NOT correct the polyuria, because the defect lies downstream of the receptor at the level of the intracellular signaling cascade and AQP2 trafficking. This distinguishes NDI from central DI, where desmopressin is effective. (c) Lithium inhibits glycogen synthase kinase 3β (GSK3β), disrupts cAMP signaling, and downregulates AQP2 gene expression, preventing adequate water channel insertion regardless of circulating ADH levels. Management includes lithium dose reduction (if possible), thiazide diuretics (paradoxically reduce urine volume by enhancing proximal reabsorption), and amiloride (blocks lithium entry through ENaC).

Question 4: APPLIED

A 55-year-old patient with congestive heart failure (CHF) has elevated ADH, elevated aldosterone, peripheral edema, and hyponatremia (Na⁺ = 125 mEq/L). Explain the apparent paradox: if both ADH and aldosterone promote water and sodium retention, why is the patient hyponatremic despite total body sodium being elevated?

Show answer

This is one of the most important and counterintuitive concepts in fluid physiology. In CHF, the failing heart reduces cardiac output and effective arterial blood volume (EABV), even though total body volume is expanded (edema, ascites). Baroreceptors and JG cells sense the low EABV and activate both the RAAS and ADH pathways as if the patient were volume-depleted. Aldosterone drives sodium retention, but this sodium distributes into the interstitial space (edema) rather than effectively expanding arterial volume. Meanwhile, ADH drives water retention disproportionately to sodium—the thirst mechanism further compounds water intake. Because water is retained in excess of sodium, the plasma sodium concentration falls (dilutional hyponatremia) even though total body sodium is actually increased. This maladaptive neurohumoral activation is the pathophysiological basis for the use of ACE inhibitors, ARBs, MR antagonists, and V₂ receptor antagonists (vaptans) in managing heart failure.

Question 5: CRITICAL THINKING

Design a thought experiment comparing two hypothetical patients: Patient A lacks all ADH production but has normal aldosterone, and Patient B lacks all aldosterone but has normal ADH. For each patient, predict the steady-state values of (a) urine volume and concentration, (b) plasma Na⁺, (c) plasma K⁺, (d) blood pressure, and (e) plasma osmolarity. Then explain which patient faces the more immediate life-threatening emergency and why.

Show answer

Patient A (no ADH, normal aldosterone): The collecting duct is impermeable to water, producing massive volumes of dilute urine (potentially 15–20 L/day at 50–100 mOsm/L). Aldosterone retains sodium normally, so plasma Na⁺ tends to rise (hypernatremia), plasma K⁺ is normal or low (aldosterone drives K⁺ secretion), and plasma osmolarity is elevated. Blood pressure may be low due to volume loss, but aldosterone partially compensates via sodium retention. This patient can survive if they have access to adequate water intake (polydipsia compensates for polyuria). Patient B (no aldosterone, normal ADH): Without aldosterone, the DCT and collecting duct cannot efficiently reabsorb sodium via ENaC. Sodium is lost in the urine, leading to hyponatremia, volume depletion, and severe hypotension. Potassium cannot be adequately secreted, causing life-threatening hyperkalemia. Metabolic acidosis develops because H⁺ secretion in the collecting duct is also impaired. ADH retains water normally, but without the osmotic pull of sodium, this compounds hyponatremia. Patient B faces the more immediate life-threatening emergency because hyperkalemia can cause fatal cardiac arrhythmias (peaked T waves, widened QRS, ventricular fibrillation) within hours, whereas Patient A's hypernatremia develops more gradually and can be partially offset by increased water consumption. This comparison underscores that while ADH is critical for water balance and osmolarity, aldosterone's role in sodium and potassium homeostasis is more immediately essential for survival.

SUMMARY

Lesson Summary

Summary

Antidiuretic hormone (ADH) and aldosterone constitute the two primary hormonal axes governing renal water and electrolyte handling. ADH, a nonapeptide released from the posterior pituitary in response to elevated plasma osmolarity or decreased blood volume, acts on V₂ receptors in the collecting duct to trigger AQP2 water channel insertion via a cAMP–PKA signaling cascade, thereby increasing water reabsorption and concentrating the urine. Aldosterone, a steroid hormone produced by the zona glomerulosa of the adrenal cortex under stimulation by the renin–angiotensin–aldosterone system (RAAS) and hyperkalemia, binds intracellular mineralocorticoid receptors and upregulates ENaC and Na⁺/K⁺-ATPase expression in the distal convoluted tubule and collecting duct, promoting sodium retention and potassium secretion.

Both systems are governed by negative feedback: restored osmolarity suppresses ADH, and restored volume/pressure suppresses renin. Clinical disorders—diabetes insipidus (ADH deficiency or resistance), SIADH (ADH excess), Conn syndrome (aldosterone excess), and Addison disease (adrenal insufficiency)—represent gain- or loss-of-function states that produce predictable patterns of osmolarity, electrolyte, and blood pressure derangements. Mastery of these two hormonal systems provides the foundation for understanding advanced topics including heart failure pathophysiology, pharmacology of ACE inhibitors and ARBs, and the clinical use of vasopressin receptor antagonists (vaptans).